These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 9371244)

  • 1. 4-hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease.
    Tait BD; Hagen S; Domagala J; Ellsworth EL; Gajda C; Hamilton HW; Prasad JV; Ferguson D; Graham N; Hupe D; Nouhan C; Tummino PJ; Humblet C; Lunney EA; Pavlovsky A; Rubin J; Gracheck SJ; Baldwin ET; Bhat TN; Erickson JW; Gulnik SV; Liu B
    J Med Chem; 1997 Nov; 40(23):3781-92. PubMed ID: 9371244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.
    Thaisrivongs S; Romero DL; Tommasi RA; Janakiraman MN; Strohbach JW; Turner SR; Biles C; Morge RR; Johnson PD; Aristoff PA; Tomich PK; Lynn JC; Horng MM; Chong KT; Hinshaw RR; Howe WJ; Finzel BC; Watenpaugh KD
    J Med Chem; 1996 Nov; 39(23):4630-42. PubMed ID: 8917652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.
    Thaisrivongs S; Janakiraman MN; Chong KT; Tomich PK; Dolak LA; Turner SR; Strohbach JW; Lynn JC; Horng MM; Hinshaw RR; Watenpaugh KD
    J Med Chem; 1996 Jun; 39(12):2400-10. PubMed ID: 8691434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H- pyran-3-yl)thiomethanes that span P1-P2' subsites in a unique mode of active site binding.
    Prasad JV; Para KS; Tummino PJ; Ferguson D; McQuade TJ; Lunney EA; Rapundalo ST; Batley BL; Hingorani G; Domagala JM
    J Med Chem; 1995 Mar; 38(6):898-905. PubMed ID: 7699705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-hydroxy-5,6-dihydro-2H-pyran-2-ones.3. Bicyclic and hetero-aromatic ring systems as 3-position scaffolds to bind to S1' and S2' of the HIV-1 protease enzyme.
    Ellsworth EL; Domagala J; Prasad JV; Hagen S; Ferguson D; Holler T; Hupe D; Graham N; Nouhan C; Tummino PJ; Zeikus G; Lunney EA
    Bioorg Med Chem Lett; 1999 Jul; 9(14):2019-24. PubMed ID: 10450973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonpeptidic potent HIV-1 protease inhibitors.
    Prasad JV; Lunney EA; Para KS; Tummino PJ; Ferguson D; Hupe D; Domagala JM; Erickson JW
    Drug Des Discov; 1996 Apr; 13(3-4):15-28. PubMed ID: 8874041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.
    Sham HL; Zhao C; Stewart KD; Betebenner DA; Lin S; Park CH; Kong XP; Rosenbrook W; Herrin T; Madigan D; Vasavanonda S; Lyons N; Molla A; Saldivar A; Marsh KC; McDonald E; Wideburg NE; Denissen JF; Robins T; Kempf DJ; Plattner JJ; Norbeck DW
    J Med Chem; 1996 Jan; 39(2):392-7. PubMed ID: 8558507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
    Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
    J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
    Ghosh AK; Swanson LM; Cho H; Leshchenko S; Hussain KA; Kay S; Walters DE; Koh Y; Mitsuya H
    J Med Chem; 2005 May; 48(10):3576-85. PubMed ID: 15887965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cycloalkylpyranones and cycloalkyldihydropyrones as HIV protease inhibitors: exploring the impact of ring size on structure-activity relationships.
    Romines KR; Morris JK; Howe WJ; Tomich PK; Horng MM; Chong KT; Hinshaw RR; Anderson DJ; Strohbach JW; Turner SR; Mizsak SA
    J Med Chem; 1996 Sep; 39(20):4125-30. PubMed ID: 8831779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based QSAR analysis of a set of 4-hydroxy-5,6-dihydropyrones as inhibitors of HIV-1 protease: an application of the receptor-dependent (RD) 4D-QSAR formalism.
    Santos-Filho OA; Hopfinger AJ
    J Chem Inf Model; 2006; 46(1):345-54. PubMed ID: 16426069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-peptidic HIV protease inhibitors: C2-symmetry-based design of bis-sulfonamide dihydropyrones.
    Janakiraman MN; Watenpaugh KD; Tomich PK; Chong KT; Turner SR; Tommasi RA; Thaisrivongs S; Strohbach JW
    Bioorg Med Chem Lett; 1998 May; 8(10):1237-42. PubMed ID: 9871742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold.
    Alterman M; Björsne M; Mühlman A; Classon B; Kvarnström I; Danielson H; Markgren PO; Nillroth U; Unge T; Hallberg A; Samuelsson B
    J Med Chem; 1998 Sep; 41(20):3782-92. PubMed ID: 9748353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
    Hagen SE; Domagala J; Gajda C; Lovdahl M; Tait BD; Wise E; Holler T; Hupe D; Nouhan C; Urumov A; Zeikus G; Zeikus E; Lunney EA; Pavlovsky A; Gracheck SJ; Saunders J; VanderRoest S; Brodfuehrer J
    J Med Chem; 2001 Jul; 44(14):2319-32. PubMed ID: 11428926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
    Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
    J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of potent pyrrolidone-based HIV-1 protease inhibitors with enhanced drug-like properties.
    Kazmierski WM; Andrews W; Furfine E; Spaltenstein A; Wright L
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5689-92. PubMed ID: 15482949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands.
    Jungheim LN; Shepherd TA; Baxter AJ; Burgess J; Hatch SD; Lubbehusen P; Wiskerchen M; Muesing MA
    J Med Chem; 1996 Jan; 39(1):96-108. PubMed ID: 8568831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
    Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
    J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of 5,6-dihydro-4-hydroxy-2-pyrones as HIV-1 protease inhibitors: the profound effect of polarity on antiviral activity.
    Hagen SE; Prasad JV; Boyer FE; Domagala JM; Ellsworth EL; Gajda C; Hamilton HW; Markoski LJ; Steinbaugh BA; Tait BD; Lunney EA; Tummino PJ; Ferguson D; Hupe D; Nouhan C; Gracheck SJ; Saunders JM; VanderRoest S
    J Med Chem; 1997 Nov; 40(23):3707-11. PubMed ID: 9371233
    [No Abstract]   [Full Text] [Related]  

  • 20. Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.
    Han Q; Chang CH; Li R; Ru Y; Jadhav PK; Lam PY
    J Med Chem; 1998 Jun; 41(12):2019-28. PubMed ID: 9622543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.